Physician profile
Kusha Davar
NPI 1790172716
$2,302.05
in general payments reported to CMS, 2019-2025
7 companies · $160 in 2025
The $160 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $358 · 2020: $185 · 2021: $425 · 2022: $677 · 2023: $375 · 2024: $122 · 2025: $160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $657.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $657.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $502.19 | 2019-2022 | |
| Melinta Therapeutics, LLC | $474.41 | 2022-2023 | Vabomere |
| Shionogi INC | $467.81 | 2021-2024 | Fetroja |
| La Jolla Pharmaceutical Company | $385.52 | 2021-2025 | Xacduro, Zevtera |
| Paratek Pharmaceuticals, INC. | $237.27 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $122.36 | 2019 | |
| Tetraphase Pharmaceuticals, INC. | $112.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kusha Davar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.